Swedbank AB grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,101,969 shares of the biopharmaceutical company's stock after purchasing an additional 54,360 shares during the period. Swedbank AB owned 0.17% of Gilead Sciences worth $194,159,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the company. nVerses Capital LLC bought a new position in Gilead Sciences in the 3rd quarter valued at about $25,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at about $29,000. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Friedenthal Financial bought a new position in Gilead Sciences in the 3rd quarter valued at about $50,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently weighed in on GILD shares. UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a research report on Thursday, November 21st. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Daiwa America upgraded shares of Gilead Sciences to a "hold" rating in a report on Monday, November 18th. Mizuho increased their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $98.39.
Check Out Our Latest Stock Analysis on GILD
Insider Buying and Selling at Gilead Sciences
In other news, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company's stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by company insiders.
Gilead Sciences Trading Up 1.9 %
Shares of GILD traded up $1.74 during mid-day trading on Wednesday, reaching $95.59. 5,585,554 shares of the company were exchanged, compared to its average volume of 6,797,380. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market capitalization of $119.13 billion, a PE ratio of 1,062.11, a PEG ratio of 1.31 and a beta of 0.18. The business has a 50 day simple moving average of $92.00 and a two-hundred day simple moving average of $85.44.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the company earned $2.29 earnings per share. The firm's revenue was up 7.0% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Recommended Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report